All In Biotech

Drug Trial Radar · NCT02475681

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acalabrutinib (ACP-196) in Combination With Obinutuzumab, and Acalabrutinib Monotherapy in Subjects With Previously Untreated CLL

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 535 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

535

Actual

Start

Jun 26, 2015

Primary completion

Feb 8, 2019

Study completion Sep 3, 2026

Sponsor

Lead sponsor
Acerta Pharma BVAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 19, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Primary objective is evaluating the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib in combination with obinutuzumab (Arm B) for the treatment of previously untreated chronic lymphocytic leukemia (CLL). Secondary objectives: 1) To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm A) versus acalabrutinib monotherapy (Arm C) based on IRC assessment of PFS per IWCLL 2008 criteria. 2)To compare obinutuzumab plus chlorambucil (Arm A) versus acalabrutinib plus obinutuzumab (Arm B) and obinutuzumab plus chlorambucil (Arm A) versus acalabrutinib monotherapy (Arm C) in terms of: IRC-assessed objective response rate (ORR); Tine to next treatment (TTNT); Overall Survival (OS)

Conditions

  • Chronic Lymphocytic Leukemia

Interventions

  • AcalabrutinibDrug

  • ObinutuzumabDrug

  • ChlorambucilDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival by IRC (Independent Review Committee) Assessment in Arm A Compared to Arm BTime frame: IRC assessments were done from randomization date until disease progression or death or IRC discontinuation date on 08Feb2019 (as the IA based on this data cutoff date showed the study crossing superiority boundary) whichever comes first up to 40 months.

Locations

155 sites in 18 countries. Site status is shown where the registry gives one.

  • Research Site

    Goodyear, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Anaheim, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Oxnard, California

  • Research Site

    Palo Alto, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Lone Tree, Colorado

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Fort Myers, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Tallahassee, Florida

  • Research Site

    Tallahassee, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Niles, Illinois

  • Research Site

    Lafayette, Indiana

  • Research Site

    Wichita, Kansas

  • Research Site

    Louisville, Kentucky

  • Research Site

    New Orleans, Louisiana

  • Research Site

    COL, Maryland

  • Research Site

    Rochester, Minnesota

  • Research Site

    Saint Cloud, Minnesota

  • Research Site

    Billings, Montana

  • Research Site

    Brick, New Jersey

  • Research Site

    Hackensack, New Jersey

  • Research Site

    Lake Success, New York

  • Research Site

    New York, New York

  • Research Site

    Blue Ash, Ohio

  • Research Site

    Canton, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Nashville, Tennessee

  • Research Site

    Austin, Texas

  • Research Site

    Bedford, Texas

  • Research Site

    Dallas, Texas

  • Research Site

    Fort Sam Houston, Texas

  • Research Site

    Houston, Texas

  • Research Site

    New Braunfels, Texas

  • Research Site

    Round Rock, Texas

Showing 40 of 155 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.